The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa

Antiviral Therapy

Volumn 13, Issue 5, 2008, Pages 625-639

  Hamers, Raph L ^a   Derdelinckx, Inge ^b   van Vugt, Michèle ^a   Stevens, Wendy ^c   Rinke de Wit, Tobias F ^a   Schuurman, Rob ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

AFRICA; ANTIVIRAL RESISTANCE; CHILD CARE; CLINICAL TRIAL; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; GENE MUTATION; GENETIC ALGORITHM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOTHER TO CHILD TRANSMISSION; NONHUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRENATAL CARE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SINGLE DRUG DOSE; VIRUS TRANSMISSION;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 49949108207     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. World Health Organisation. Treating 3 million by 2005: making it happen: the WHO strategy. (Accessed 15 September 2007). Available from http://www.who.int/3by5/publications/documents/en/ 3by5StrategyMakingItHappen.pdf. Geneva, 2003.
3. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interentions in the health sector: progress report, April 2007. (Accessed 15 September 2007). Available from http://www.who.int/hiv/ mediacentre/univeral_access_progress_report_en.pdf. Geneva, 2007.
4. Derdelinckx I, Van LK, Maes B, et al. Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response. J Acquir Immune Defic Syndr 2004; 37:1664-1666.
5. Little SJ, Holte S, Roury JP, et al. Antiretroviral-drug resistance amon patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
6. Wensing AM, van de Vijver, DA, Aggarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
7. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13-W23.
8. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242:1168-1171.
9. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988; 242:1171-1173.
10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
11. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122.
12. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001; 14:23-28.
13. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-125.
14. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision. (Accessed 1 November 2007). Available from http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Geneva, 2006.
15. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
16. Renjifo B. HIV-1 subtypes and recombinants. In AIDS in Africa, 2nd edn. Edited by M Essex, S Mboup, PJ Kanki, RG Marlink and SD Tlou. New York: Springer 2002; pp. 138-157.
17. Fonjungo PN, Dash BC, Mpoudi EN, et al. Molecular screening for HIV-1 group N and simian immunodeficiency virus cpz-like virus infections in Cameroon. AIDS 2000; 14:750-752.
18. Jaffe HW, Schochetman G. Group O human immunodeficiency virus-1 infections. Infect Dis Clin North Am 1998; 12:39-46.
19. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. Science 2000; 288:55-56.
20. Grobler J, Gray CM, Rademeyer C, et al. Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis 2004; 190:1355-1359.
21. Hu DJ, Subbarao S, Vanichseni S, et al. Frequency of HIV-1 dual subtype infections, including intersubtype superinfections, among injection drug users in Bangkok, Thailand. AIDS 2005; 19:303-308.
22. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
23. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-224.
24. Dumans AT, Soares MA, Machado ES, et al. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis 2004; 189:1232-1238.
25. Gonzalez LM, Brindeiro RM, Aguiar RS, et al. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 2004; 48:3552-3555.
26. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2:e112.
27. Kantor R, Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003; 5:25-35.
28. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000; 38:3919-3925.
29. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997; 71:8893-8898.
30. Witvrouw M, Pannecouque C, Van LK, Desmyter J, De CE, Vandamme AM. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 1999; 13:1477-1483.
31. Holguin A, Sune C, Hamy F, Soriano V, Klimkait T. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol 2006; 36:264-271.
32. Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12:1109-1111.
33. Kinomoto M, Appiah-Opong R, Brandful JA, et al. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis 2005; 41:243-251.
34. Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 1998; 14:157-162.
35. Velazquez-Campoy A, Todd MJ, Vega S, Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A 2001; 98:6062-6067.
36. Velazquez-Campoy A, Vega S, Freire E. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 2002; 41:8613-8619.
37. Vergne L, Stuyver L, Van HM, Butel C, Delaporte E, Peeters M. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol 2006; 36:43-49.
38. van de Vijver, DA, Wensing AM, Angarano G, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006; 41:352-360.
39. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20:F9-F13.
40. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50:4182-4185.
41. Eshleman SH, Guay LA, Wang J, et al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 2005; 40:24-29.
42. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192:30-36.
43. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some womens and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192:24-29.
44. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19:2167-2169.
45. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1-F5.
46. Snoeck J, Kantor R, Shafer RW, et al. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006; 50:694-701.
47. Vergne L, Snoeck J, Aghokeng A, et al. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol 2006; 46:53-62.
48. Bourgeois A, Laurent C, Mougnutou R, et al. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther 2005; 10:335-341.
49. Fischer A, Karasi JC, Kibibi D, et al. Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002. HIV Med 2006; 7:64-66.
50. Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16:1363-1370.
51. Laurent C, Ngom Gueye NF, Ndour CT, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005; 38:14-17.
52. Laurent C, Kouanfack C, Vergne L, et al. Antiretroviral drug resistance and routine therapy, Cameroon. Emerg Infect Dis 2006; 12:1001-1004.
53. Spacek LA, Shihab HM, Kamya MR, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006; 42:252-259.
54. DART Virology Group and Trial Team virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399.
55. Seyler C, dje-Toure C, Messou E, et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 2007; 21:1157-1164.
56. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
57. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 2007; 45:1492-1498.
58. Kantor R, Zijenah LS, Shafer RW et al. HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18:1407-1413.
59. Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2001; 26:501-506.
60. Vergne L, Malonga-Mouellet G, Mistoul I, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 2002; 29:165-168.
61. Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19:487-494.
62. Chaix ML, Rouet F, Kouakoussui KA, et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cote d'Ivoire. Pediatr Infect Dis J 2005; 24:1072-1076.
63. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46:187-193.
64. Lwembe R, Ochieng W, Panikulam A, et al. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol 2007; 79:865-872.
65. Cohen GM. Access to diagnostics support of HIV/AIDS and tuberculosis treatment in developing countries. AIDS 2007; 21 Suppl 4:S81-S87.
66. Nugent R, Pickett J, Back E. Drug resistance as a global health policy priority. Center for Global Development. Washington, January 2008. (Accessed 15 January 2008). Available from http://www.cgdev.org/doc/ ghprn/Concept%20Paper.pdf.
67. World Health Organization. The orld Health Report 2006. (Accessed 1 November 2007). Available from http://www.who.int/whr/2006/whr06_en.pdf. Geneva, 2006.
68. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347.
69. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
70. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37:1112-1118.
71. Bisson GP, Frank I, Gross R, et al. Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 2006; 20:1333-1336.
72. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS 2005; 19:1243-1249.
73. Breen RA, Swaden L, Ballinger J, Lipman MC. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 2006; 66:2299-2308.
74. Wallis CL, Bell C, Boulmé R, et al. Emerging ART Drug Resistance in Subtype C: Experience from the 2 Clinics in Johannesburg, South Africa. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 661.
75. Cozzi-Lepri A, Phillips AN, Ruiz et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21:721-732.
76. Wensing AM, Vercauteren J, van de Vijver D, et al. First representative prospective surveillance data on HIV baseline drug resistance from 17 countries Europe:the SPREAD programme. 4th Europe HIV drug Resistance Workshop. 29-31 March 2006, Monte Carlo, Monaco. Abstract 1.
77. Little SJ, May S, Hecht F, et al. Incease in transmitted NNRTI drug resistance among recently HIV infected patients from North America and Australia. Antivir Ther 2006; 11 Suppl 1:S110.
78. Ross LL, Florance A, Wine B, et al. Prevalence of HIV-1 drug resistance-associated mutations in a large cohort of antiretroviral therapy (ART) naive HIV-infected individuals in the United States from 2000-2004. Antivir Ther 2006; 11 Suppl 1:S120.
79. Bowles E, Wensing AM, van de Vijver DA, Boulmé R, Schuurman R, Boucher CA. WATCH: a worldwide database for collecting and analysing data on transmission of drug resistant HIV using standardized methods. XVIth International AIDS Conference. 3-48 August 2006, Toronto, Canada. Abstract MOPE0388.
80. Adje-Toure C, Bile CE, Borger M, et al. Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02_AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2003, 34:111-113.
81. Bellocchi MC, Forbici F, Palombi L, et al. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J Med Virol 2005; 76:452-458.
82. Bussmann H, Novitsky V, Wester W, et al. HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana. Antivir Chem Chemother 2005; 16:103-115.
83. Gordon M, de Oliveira T, Bishop K, et al. Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies. J Virol 2003; 77:2587-2599.
84. Handema R, Terunuma H, Kasolo F, et al. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses 2003; 19:151-160.
85. Koizumi Y, Ndembi N, Miyashita M, et al. Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr 2006; 43:15-22.
86. Konings FA, Zhong P, Agwara M, et al. Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Res Hum Retroviruses 2004; 20:105-109.
87. Maslin J, Rogier C, Caron M, Grandadam M, Koeck JL, Nicand E. Antiretroviral drug resistance among drug-naive HIV-1-infected individuals in Djibouti (Horn of Africa). Antivir Ther 2005; 10:855-859.
88. Perch LA, Hoffman IF, Jere CS, et al. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi. AIDS Res Hum Retroviruses 2005; 21:799-805.
89. Pillay C, Bredell H, McIntyre J, Gray G, Morris L. HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Res Hum Retroviruses 2002; 18:605-610.
90. Somi G, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar Es Salaam, Tanzania. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 655.
91. Toni T, Masquelier B, Bonard D, et al. Primary HIV-1 drug resistance in Abidjan (Cote d'Ivoire): a genotypic and phenotypic study. AIDS 2002; 16:488-491.
92. Toni TD, Recordon-Pinson P, Minga A, et al. Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Cote d'Ivoire: ANRS 1257 study. AIDS Res Hum Retroviruses 2003; 19:713-717.
93. Vergne L, Kane CT, Laurent C, et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 2003; 17 Suppl. 3:S31-S38.
94. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 2006; 11:575-579.
95. Vessiere A, Nerrienet E, Kfutwah A, et al. HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaounde, Cameroon. J Acquir Immune Defic Syndr 2006; 42:256-258.
96. Vidal N, Mulanga C, Bazepeo SE, et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses 2006; 22:202-206.
97. Vidal N, Niyongabo T, Nduwimana J, et al. HIV type 1 diversity and antiretroviral drug resistance mutations in Burundi. AIDS Res Hum Retroviruses 2007; 23:175-180.
98. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19:1-14.
99. Hastings IM, Lalloo D, Khoo SH. Will ART rollout in Africa drive an epidemic of drug resistant HIV? AIDS 2006; 20:1354-1356.
100. Vardavas R, Blower S. The emergence of HIV transmitted resistance in Botswana: "When will the WHO detection threshold be exceeded?" PLoS ONE 2007; 2:e152.
101. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683-1689.
102. Ghosn J, Pellegrin I, Goujard C, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20:159-170.
103. HIV-infected pregnant women and vertical transmission in Europe since 1986. European collaborative study. AIDS 2001; 15:761-770.
104. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002; 288:189-198.
105. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285:2083-2093.
106. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
107. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-868.
108. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-1957.
109. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004; 20:595-599.
110. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35:126-130.
111. Gordon M, Graham N, Bland R, et al. Surveillance of resistance in KZN South Africa, including mother-infant pairs 6 weeks after single-dose NVP. Antivir Ther 2004; 9:S80.
112. Lee EJ, Kantor R, Zijenah L, et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis 2005; 192:1260-1264.
113. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, LA, USA. Abstract 38.
114. McIntyre J, Martinson N, Gray GE, et al. Addition of short course Combivir (CBV) to single dose viramune (sdNVP) for the prevention of mother to child transmission (MTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. 3rd IAS Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brazil. Abstract TuFo0204.
115. Morris L, Martinson N, Pillay C, et al. Persistence of nevirapine resistance mutations 6 months following single dose nevirapine. XVth International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract ThOrB1353.
116. Sullivan J. South African Nevirapine Trial: Selection of resistance mutations. XIVth International AIDS Conference. 7-12 July 2002, Barcelona, Spain. Abstract LbPeB9024.
117. Toni TD, Masquelier B, Lazaro E, et al. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Cote d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. AIDS Res Hum Retroviruses 2005; 21:1031-1034.
118. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006; 193:482-487.
119. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access: recommendations for a public health approach. (Accessed 1 September 2007). Available from http://www.who.int/ hiv/pub/mtct/guidelines/en. Geneva, 2006.
120. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-1705.
121. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-1021.
122. Troyer R, Lalonde M, Kyeyune F, et al. High frequency of nevirapine resistant mutations in the HIV quasi species found in NVP-treated participants of an MTCT Ugandan cohort. Antivir Ther 2005; 10:S14.
123. Eshleman SH, Hoover DR, Hudelson SE, et al. Development of nevirapine resistance in infants is reduced by use of infant-only sinfle-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis 2006; 193:479-481.
124. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
125. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
126. Covaadia A, Marais B, Abrams E, et al. Virologic reponse to NNRTi treatment among women who took single-dose nevirapine 18 to 36 months earlier. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 641.
127. Kuhn L, Sinkala M, Kankasa MP, Kasonde P, Thea DM, Aldrovandi GM. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission. J Acquir Immune Defic Syndr 2006; 42:260-262.
128. Martinson NA, Ekouevi DK, Dabis F, et al. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2007; 45:206-209.
129. Eure C, Bakaki P, McConnell M, et al. Effectiveness of repeat single-dose nevirapine in subsequent pregnancies among Uganda women. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February, 2006, Denver, CO, ISS-A. Abstract 125.
130. Katabira ET, Oelrichs RB. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS 2007; 21 Suppl 4:S5-S10.
131. Koenig SP, Kuritzkes DR, Hirsch MS, et al. Monitoring HIV treatment in developing countries. BMJ 2006; 332:602-604.
132. Global HIV Drug Resistance Surveillance Network (HIVResNet). (Accessed 1 December 2007). Available from http://who.int/drugresistance/hivaids/ network/en.
133. Linking African and Asian Societits for an Enhanced Response to HIV/AIDS (LAASER). (Accessed 1 December 2007). Available from http://www://laaserhivaids.org/
134. Gallant JE. Antiretroviral drug resistance and resistance testing. Top HIV Med 2005; 13:138-142.